Tumor angiogenesis and molecular targets for therapy
- PMID: 19273326
- DOI: 10.2741/3504
Tumor angiogenesis and molecular targets for therapy
Abstract
Tumors produce multiple angiogenic factors to induce neovascularization by angiogenesis, vasculogenesis and vascular remodeling. Although tumors utilize similar mechanisms as normal growing tissues, tumor blood vessels usually appear as malformed vasculatures that have several distinctive features including a high degree of disorganization, lack of clear separation between arterioles and venules, lack of appropriate coating with mural cells, high permeability, and composition of mosaic cell types, which might express specific markers. These unusual features of tumor blood vessels offer a great opportunity for therapeutic intervention and might paradoxically restrict cytotoxic drug delivery. Following an initial clinical success of bevacizumab in combination with chemotherapy for the treatment of human colorectal cancer, several other anti-angiogenesis agents are now available in the clinic. Understanding basic mechanisms of tumor angiogenesis, defining novel and accurate molecular targets, designing optimal clinical trials, and minimizing side effects are crucial issues for a further successful development of anti-angiogenic compounds for the treatment of various human cancers.
Similar articles
-
Molecular mechanisms and therapeutic development of angiogenesis inhibitors.Adv Cancer Res. 2008;100:113-31. doi: 10.1016/S0065-230X(08)00004-3. Adv Cancer Res. 2008. PMID: 18620094 Review.
-
Translating angiogenesis research into the clinic: the challenges ahead.Br J Radiol. 2003;76 Spec No 1:S3-10. doi: 10.1259/bjr/68078705. Br J Radiol. 2003. PMID: 15456709 Review.
-
Anti-angiogenic therapies for children with cancer.Curr Cancer Drug Targets. 2010 Dec;10(8):879-89. doi: 10.2174/156800910793357899. Curr Cancer Drug Targets. 2010. PMID: 20718702 Review.
-
Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.Mol Aspects Med. 2011 Apr;32(2):71-87. doi: 10.1016/j.mam.2011.04.001. Epub 2011 Apr 22. Mol Aspects Med. 2011. PMID: 21540050 Review.
-
Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets.Clin Exp Metastasis. 2012 Oct;29(7):657-62. doi: 10.1007/s10585-012-9500-6. Epub 2012 Jun 13. Clin Exp Metastasis. 2012. PMID: 22692562 Free PMC article.
Cited by
-
Sanguinarine Regulates Tumor-Associated Macrophages to Prevent Lung Cancer Angiogenesis Through the WNT/β-Catenin Pathway.Front Oncol. 2022 Jun 30;12:732860. doi: 10.3389/fonc.2022.732860. eCollection 2022. Front Oncol. 2022. PMID: 35847885 Free PMC article.
-
Cooperative signaling between Slit2 and Ephrin-A1 regulates a balance between angiogenesis and angiostasis.Mol Cell Biol. 2011 Feb;31(3):404-16. doi: 10.1128/MCB.00667-10. Epub 2010 Dec 6. Mol Cell Biol. 2011. PMID: 21135133 Free PMC article.
-
Fibroblast activation protein-α, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations.Mol Oncol. 2016 Jan;10(1):40-58. doi: 10.1016/j.molonc.2015.08.001. Epub 2015 Aug 11. Mol Oncol. 2016. PMID: 26304112 Free PMC article.
-
Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients.Materials (Basel). 2021 May 8;14(9):2440. doi: 10.3390/ma14092440. Materials (Basel). 2021. PMID: 34066710 Free PMC article. Review.
-
Adipocyte and lipid metabolism in cancer drug resistance.J Clin Invest. 2019 Jul 2;129(8):3006-3017. doi: 10.1172/JCI127201. eCollection 2019 Jul 2. J Clin Invest. 2019. PMID: 31264969 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
